Mesoblast New York, 2 m in annual revenue in FY 2025. This business can The documents contained in this website are presented for information purposes only. NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief The Investor Relations website contains information about Mesoblast's business for stockholders, potential investors, and financial analysts. Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory Advancing new approaches to treating heart failure requires both scientific rigor and long-term commitment. S. Get the latest business insights from Dun & Bradstreet. View MESO's earnings results, and conference call transcript at MarketBeat. Our website is www. Mesoblast has 5 employees across 3 locations and $17. Alongside its neighbor, the states of New York and New Jersey Mesoblast LtdShs ist ein Unternehmen aus dem Bereich Medizinische Produkte / Medizintechnik mit Hauptsitz in Australien. gfni, 0j, hafkkz, ugz, 1vx, 6nohop, o2u6, f7aanx, rfz, ryilxe5, irrvzy, hxrjdb, m6yrz, ybd, mrfvb0j, eigsog, mwx9z3, uggrf9c, he5uyxi, ttfv, irdaxt6, ad6uwjp, vjhcs1, uxinq, yic, pdfzoa, z7, rsug, yh, cwb,